Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells

Biochemical Pharmacology

Volumn 79, Issue 12, 2010, Pages 1746-1758

  López Royuela, Nuria ^a   Pérez Galán, Patricia ^b   Galán Malo, Patricia ^a   Yuste, Victor J ^c   Anel, Alberto ^a   Susín, Santos A ^d,e   Naval, Javier ^a   Marzo, Isabel ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT DE NEUROCIÈNCIES   (Spain)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

AIF; Bcl 2 family proteins; BH3 only proteins; Caspases; Doxorubicin

Indexed keywords

BH3 PROTEIN; CASPASE; DOXORUBICIN; PROTEIN BAK; PROTEIN MCL 1; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 77951294919     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.02.010     Document Type: Article

References (55)

1. Gamen S., Anel A., Lasierra P., Alava M.A., Martinez-Lorenzo M.J., Piñeiro A., et al. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997, 417:360-364.
2. Gamen S., Anel A., Pérez-Galán P., Lasierra P., Johnson D., Piñeiro A., et al. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes ΔΨm loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 2000, 258:223-235.
3. Wei M.C., Zong W.-X., Cheng E.H.-Y., Lindsten T., Panoutsakopoulou V., Ross A.J., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
4. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003, 302:1036-1038.
5. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
6. van Delft M.F., Smith D.P., Lahoud M.H., Huang D.C., Adams J.M. Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. Cell Death Differ 2009.
7. Herrant M., Jacquel A., Marchetti S., Belhacène N., Colosetti P., Luciano F., et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004, 23:7863-7873.
8. Clohessy J.G., Zhuang J., Brady H.J. Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. Br J Haematol 2004, 125:655-665.
9. Lassus P., Opitz-Araya X., Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002, 297:1352-1354.
10. Lin C.F., Chen C.L., Chang W.T., Jan M.S., Hsu L.J., Wu R.H., et al. Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramide and etoposide-induced apoptosis. J Biol Chem 2004, 279:40755-40761.
11. Robertson J.D., Enoksson M., Suomela M., Zhivotovsky B., Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 2002, 277:29803-29809.
12. Gomez-Benito M., Marzo I., Anel A., Naval J. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol Pharmacol 2005, 67:1991-1998.
13. Cheng J., Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990, 10:5502-5509.
14. Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K., Ishikawa F., et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992, 79:2378-2383.
15. Gomez-Benito M., Balsas P., Carvajal-Vergara X., Pandiella A., Anel A., Marzo I., et al. Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal 2007, 19:844-854.
16. Balsas P., Lopez-Royuela N., Galan-Malo P., Anel A., Marzo I., Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 2009, 77:804-812.
17. Krajewski S., Zapata J.M., Reed J.C. Detection of multiple antigens on western blots. Anal Biochem 1996, 236:221-228.
18. Perez-Galan P., Marzo I., Giraldo P., Rubio-Felix D., Lasierra P., Larrad L., et al. Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. Leukemia 2002, 16:2106-2114.
19. Piqué M., Barragán M., Dalmau M., Bellosillo B., Pons G., Gil J. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett 2000, 480:193-196.
20. Griffiths G.J., Dubrez L., Morgan C.P., Jones N.A., Whitehouse J., Corfe B.M., et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999, 144:903-914.
21. Panaretakis T., Pokrovskaja K., Shoshan M.C., Grander D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002, 277:44317-44326.
22. Yamaguchi H., Paranawithana S.R., Lee M.W., Huang Z., Bhalla K.N., Wang H.-G. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 2002, 62:466-471.
23. Alves N.L., Derks I.A., Berk E., Spijker R., van Lier R.A., Eldering E. The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 2006, 24:703-716.
24. Marzo I., Perez-Galan P., Giraldo P., Rubio-Felix D., Anel A., Naval J. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J 2001, 359:537-546.
25. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
26. Garcia-Calvo M., Peterson E.P., Leiting B., Ruel R., Nicholson D.W., Thornberry N.A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998, 273:32608-32613.
27. Berger A.B., Sexton K.B., Bogyo M. Commonly used caspase inhibitors designed based on substrate specificity profiles lack selectivity. Cell Res 2006, 16:961-963.
28. Talanian R.V., Quinlan C., Trautz S., Hackett M.C., Mankovich J.A., Banach D., et al. Substrate specificities of caspase family proteases. J Biol Chem 1997, 272:9677-9682.
29. Stuhmer T., Chatterjee M., Hildebrandt M., Herrmann P., Gollasch H., Gerecke C., et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005, 106:3609-3617.
30. Xiang J., Chao D.T., Korsmeyer S.J. Bax-induced cell death may not require interleukin 1β-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996, 93:14559-14563.
31. Brimmell M., Mendiola R., Mangion J., Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998, 16:1803-1812.
32. Moulding D.A., Giles R.V., Spiller D.G., White M.R.H., Tidd D.M., Edwards S.W. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood 2000, 96:1756-1763.
33. Derenne S., Monia B., Dean N.M., Taylor J.K., Rapp M.J., Harousseau J.L., et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002, 100:194-199.
34. Steimer D.A., Boyd K., Takeuchi O., Fisher J.K., Zambetti G.P., Opferman J.T. Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 2009, 113:2805-2815.
35. Nijhawan D., Fang M., Traer E., Zhong Q., Gao W., Du F., et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003, 17:1475-1486.
36. Gomez-Bougie P., Wuilleme-Toumi S., Menoret E., Trichet V., Robillard N., Philippe M., et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007, 67:5418-5424.
37. Menoret E., Gomez-Bougie P., Geffroy-Luseau A., Daniels S., Moreau P., Le Gouill S., et al. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006, 108:1346-1352.
38. Iglesias-Serret D., Pique M., Gil J., Pons G., Lopez J.M. Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys 2003, 417:141-152.
39. Hsu Y.T., Youle R.J. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 1997, 272:13829-13834.
40. Lakhani S.A., Masud A., Kuida K., Porter G.A., Booth C.J., Mehal W.Z., et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006, 311:847-851.
41. Ekert P.G., Read S.H., Silke J., Marsden V.S., Kaufmann H., Hawkins C.J., et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol 2004, 165:835-842.
42. Bellosillo B., Villamor N., Lopez-Guillermo A., Marce S., Bosch F., Campo E., et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002, 100:1810-1816.
43. Dewson G., Snowden R.T., Almond J.B., Dyer M.J., Cohen G.M. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 2003, 22:2643-2654.
44. Murphy K.M., Streips U.N., Lock R.B. Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation. J Biol Chem 2000, 275:17225-17228.
45. Meijerink J.P.P., Mensink E.J.B.M., Wang K., Sedlak T.W., Sloetjes A.W., de Witte T., et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998, 91:2991-2997.
46. Merino D., Giam M., Hughes P.D., Siggs O.M., Heger K., O'Reilly L.A., et al. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 2009, 186:355-362.
47. Cartron P.F., Gallenne T., Bougras G., Gautier F., Manero F., Vusio P., et al. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 2004, 16:807-818.
48. Kim H., Rafiuddin-Shah M., Tu H.-C., Jeffers J.R., Zambetti G.P., Hsieh J.J.D., et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006, 8:1348-1358.
49. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999, 104:263-269.
50. Vayssade M., Haddada H., Faridoni-Laurens L., Tourpin S., Valent A., Bènard J., et al. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005, 116:860-869.
51. Kawahara M., Hori T., Chonabayashi K., Oka T., Sudol M., Uchiyama T. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008, 112:3856-3866.
52. Karpinich N.O., Tafani M., Schneider T., Russo M.A., Farber J.L. The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax. J Cell Physiol 2006, 208:55-63.
53. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
54. Czabotar P.E., Lee E.F., van Delft M.F., Day C.L., Smith B.J., Huang D.C.S., et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007, 104:6217-6222.
55. Craig R.W. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002, 16:444-454.